History of depression alone should not stop patients accessing GLP-1RA therapy, a large cohort study has found.

The retrospective analysis, published in Diabetes, Obesity and Metabolism[link here], found GLP-1RAs were not associated with higher suicidality risk than SGLT2 inhibitors in patients with T2D and pre-existing depression.

The study also found GLP-1RAs were associated with a 14% lower risk of antipsychotic use and lower all-cause mortality compared with SGLT2is, findings the authors said were clinically informative for an already vulnerable population.

Researchers from Chung Shan Medical University Hospital in Taiwan drew on data from TriNetX, a large federated health records network, to track mental health outcomes in T2D patients who had received antidepressant treatment in the six months before starting a GLP-1RA. After 1:1 propensity score matching, two groups of 34,761 patients were compared.

Key results

Psychiatrist Dr Yu Chang and colleagues noted that suicidality was “uncommon, multifactorial and less directly tied to day-to-day depressive symptom burden.” Antipsychotic use, they argued, was a more clinically sensitive proxy, reflecting decisions made when depressive symptoms remained insufficiently controlled despite antidepressant therapy, though they acknowledged it was an imperfect measure.

Subgroup analysis found no age-based trends, but the association between GLP-1RA use and lower antipsychotic use was stronger in men than women (HR 0.80 vs 0.90).

Why might GLP-1RAs help?

The authors noted that depression and T2D share overlapping pathophysiology, including chronic low-grade inflammation. GLP-1 receptors are also expressed in brain regions involved in mood regulation and reward processing, raising the possibility of central effects beyond peripheral metabolic actions.

The data were reassuring but had important limitations. The study was retrospective and observational, meaning causality could not be established, and it tracked only short-term psychiatric outcomes.

The authors stressed that population-level trends should not replace individual clinical assessment. “Individualised psychiatric assessment and follow-up remain important, particularly for patients with severe, unstable or recently worsening depression,” they wrote.

Despite those caveats, the authors said the findings supported access to GLP-1RAs in this group. Treated depression alone, they concluded, should not lead to routine avoidance of GLP-1RAs.